Your browser doesn't support javascript.
loading
89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer.
Kok, I C; Hooiveld, J S; van de Donk, P P; Giesen, D; van der Veen, E L; Lub-de Hooge, M N; Brouwers, A H; Hiltermann, T J N; van der Wekken, A J; Hijmering-Kappelle, L B M; Timens, W; Elias, S G; Hospers, G A P; Groen, H J M; Uyterlinde, W; van der Hiel, B; Haanen, J B; de Groot, D J A; Jalving, M; de Vries, E G E.
Afiliação
  • Kok IC; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Hooiveld JS; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • van de Donk PP; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Giesen D; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • van der Veen EL; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Lub-de Hooge MN; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Brouwers AH; Department of Medical Imaging Center, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Hiltermann TJN; Department of Pulmonary Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • van der Wekken AJ; Department of Pulmonary Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Hijmering-Kappelle LBM; Department of Pulmonary Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Timens W; Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Elias SG; Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Hospers GAP; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Groen HJM; Department of Pulmonary Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Uyterlinde W; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van der Hiel B; Department of Nuclear Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Haanen JB; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • de Groot DJA; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Jalving M; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • de Vries EGE; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Electronic address: e.g.e.de.vries@umcg.nl.
Ann Oncol ; 33(1): 80-88, 2022 01.
Article em En | MEDLINE | ID: mdl-34736925
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Idioma: En Ano de publicação: 2022 Tipo de documento: Article